With 340B Ruling, Corrupt Hospitals Get What They Deserve

  • Townhall | by: Peter Pitts |
  • 04/06/2023 12:00 AM
With 340B Ruling, Corrupt Hospitals Get What They Deserve
Photo Credit: AP/Carolyn Kaster

A federal appeals court just dealt a huge blow to hospitals that pad their bottom line with cash intended for needy patients.

Federal law requires drug makers to sell their medications at steep discounts to hospitals and clinics that serve poor communities. The court threw out regulations requiring drug makers to sell drugs at a discount to each and every pharmacy an eligible hospital contracts with, regardless of whether the drugs are for poor patients.

The ruling is great news for Americans who need care but have a hard time affording it. It's also a cautionary tale about how legislation intended to help the poor got twisted bureaucratically into a way for hospital administrators to get rich.

Congress created the system in question by enacting Section 340B of the Public Health Service Act of 1992. Under 340B, hospitals that serve needy patients, including the uninsured and underserved, can buy drugs from manufacturers at highly discounted rates, similar to those offered to Medicare. On average, 340B participants receive 59% off list prices.
Unfortunately, 340B doesn't explicitly require hospitals to pass on discounts to needy patients or otherwise use the savings to provide free or discounted care. Instead, hospitals and pharmacies use 340B to buy cheap drugs for which they often charge full freight.

 
Sign Up for Our Email Newsletter

RECENT NEWS

Sorry, but the ‘drugs from Canada’ don’t work

Sorry, but the ‘drugs from Canada’ don’t work

“Drugs from Canada” is a policy that won’t work. And a political soundbite that won’t die....  Read more

Product Failure Is Not Process Failure

Product Failure Is Not Process Failure

FDA be nimble. FDA be quick. FDA jump over the bureaucratic schtick....  Read more

The Future of U.S. Biopharmaceutical Innovation and Supply Chain Security Lies in the Abraham Accords Region

The Future of U.S. Biopharmaceutical Innovation and Supply Chain Security Lies in the Abraham Accords Region

Congress must enact legislation that pushes our country forward, builds bridges where there are gaps, and leverages strat...  Read more

DRUGWONKS BLOG